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Correct staging of patients with prostate cancer is important for treatment planning 
and prognosis. Although bone scintigraphy with 99mTc-phosphonates (BS) is generally 
advised for staging by guidelines in high-risk prostate cancer, this imaging technique 
is hampered by a high rate of inconclusive results and moderate accuracy. Potentially 
better imaging techniques for detection of bone metastases such as 18F-sodiumfluoride 
PET/CT (NaF PET/CT) are therefore being evaluated. In this observational cohort study 
we evaluate the performance and clinical impact of both BS and NaF PET/CT in primary 
staging of patients with prostate cancer.
Methods
The first of two cohorts consisted of patients who received a BS while the second 
included patients who received a NaF PET/CT for primary staging of prostate cancer. 
For both cohorts the number of positive, negative and equivocal findings, calculated 
diagnostic performance of the imaging modality in terms of sensitivity and specificity, 
as well as the impact on clinical management were studied. The ranges of the diagnostic 
performance were calculated both assuming that equivocal findings were positive and 
assuming that they were negative for bone metastases. For the NaF PET/CT cohort the 
number of patients with signs of lymph node metastases on low dose CT were also 
recorded, including the impact of these findings on clinical management. 
Results
One-hundred-and-four patients underwent NaF PET/CT, whereas 122 patients underwent 
BS. Sensitivities of 97-100% and 84-95% and specificities of 98-100% and 72-100% were 
found on a patient basis for detection of bone metastases with NaF PET/CT and BS 
, respectively. Equivocal findings warranted further diagnostic procedures in 2% of 
the patients in the NaF cohort and in 16% in the BS cohort. In addition NaF PET/CT 
demonstrated lymph node metastases in 50% of the included patients, of which 25% 
showed evidence of lymph node metastases only.
Conclusion
Our data indicate better diagnostic performance of NaF PET/CT compared to BS for 
detection of bone metastases in primary staging of prostate cancer patients. Less 
equivocal findings are encountered with NaF PET/CT. Moreover, NaF PET/CT has 
additional value over BS since lymph node metastases are encountered frequently.
514137-L-bw-Wondergem




Prostate cancer is a highly prevalent malignancy in western countries, especially in 
older men. Of all types of cancer in men, prostate cancer has the highest incidence, and 
its mortality is surpassed only by lung and colon cancer (European Cancer Observatory, 
http://eu-cancer.iarc.fr/). In aggressive forms of prostate cancer, haematogenous spread 
occurs primarily to the hematopoietic red marrow of the skeleton. The presence of such 
metastatic bone disease markedly influences prognosis, and early diagnosis of skeletal 
involvement is necessary for appropriate patient management (1).
Since the 1960s it is recognised that bone scintigraphy (BS) is capable of detecting bone 
metastases well before radiological change. Successful bone imaging was achieved in 
1961 by Fleming et al. (2) using 85Sr. Due to the large radiation burden and slow clearance 
of tracer from the blood pool this radioisotope was far from ideal. A few years later 87mSr 
and 18F were introduced as alternatives for 85Sr (3, 4).  However, for 87mSr the slow tracer 
extraction from soft tissues still prohibited sufficient image quality. 18F with its fast 
blood clearance and high skeletal uptake resulted in more satisfactory images. However 
the low availability of this isotope, which is cyclotron produced and has a relatively low 
half-life of 110 minutes, and the relatively high energy of the emitted photons of 18F (511 
keV), which is not ideal for detection with an Anger gamma-camera, prevented its use in 
clinical routine. In 1971 the first radiopharmaceutical based on a phosphonate labelled 
with 99mTc became available (5). For that time, 99mTc had ideal properties for clinical use. 
First, there was a good availability of this isotope, since it was used for other nuclear 
medicine procedures, which had become routine clinical practice and second, the 
relatively low photon energy (140 keV) with a half-life of 6 hours was suitable for imaging 
with an Anger gamma-camera. Further developments resulted in introduction of 99mTc-
methylene diphosphonate (99mTc-MDP) and 99mTc-hydroxymethylene diphosphonate 
(99mTc-HDP), which are the most commonly used tracers for bone imaging with a 
gamma-camera (6, 7).
For decades European and U.S. guidelines recommend bone scintigraphy with 
99mTc-phosphonates for bone metastasis assessment, which, if necessary can be 
complemented by radiographic survey (8, 9). A closer look at the present guidelines 
reveals that the guidelines are mainly based on 30 years-old studies which found that 
BS was the most sensitive diagnostic method at that time and on arguments involving 
the clinical impact of BS, for which the pre-test probability for positive findings is used 
as a surrogate (10, 11). The wide availability and technical improvements of Positron 
Emission Tomography / Computed Tomography (PET/CT) cameras after the introduction 
of 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) in standard medical imaging in the late 
1900s and early 2000s and the increasing insights in the diagnostic value of 99mTc-MDP 
and 99mTc-HDP bone scans, with a moderate sensitivity and poor specificity, resulted in 
renewed interest in 18F as a bone tracer in medical imaging. Although 18F-sodiumfluoride 
(NaF) PET/CT performed better than 99mTc-HDP bone scan (BS) in comparative studies, 
data is still limited due to relatively small studied cohorts and the inclusion of mixed 
patient populations (12-15).
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In January 2014 NaF PET/CT for detection of bone metastases was introduced in our 
clinical practice. Before this date BS was routinely performed. For all patients that 
received a NaF PET/CT on our department patient data was prospectively entered in 
a database for quality assessment and educational purposes. In this study we present 
the data of a cohort of patients that received NaF PET/CT and a cohort of patients that 
received BS for primary staging of prostate cancer. For both cohorts, the number of 
positive, negative and equivocal findings, found diagnostic performance of the imaging 
modality, including sensitivity and specificity, and impact on clinical management are 
reported. For the NaF PET/CT cohort the number of patients with signs of lymph node 
metastases on low dose CT are also reported, including the impact of these findings on 
clinical management. 
MATERIAL AND METHODS
Both cohorts included patients who received either BS or NaF PET/CT for initial staging 
of histopathologically or clinically proven prostate cancer. Clinically proven prostate 
cancer was defined as elevated PSA >20 ng/ml and a clear prostate tumour by digital 
exam. The retrospective BS cohort included all consecutive patients from January 2011 
till April 2012, while patients were included in the NaF PET/CT from January 2014 till July 
2016. Patients who had a second malignancy, except basal cell carcinoma of the skin, or 
for whom no follow-up data were available were excluded from the analysis. All patients 
gave written informed consent for the use of their anonymous data for scientific 
purposes. Besides the standard imaging protocol and standard clinical management no 
additional measurements or actions affecting the patient were performed. The study 
passed the local scientific board and approval of the local ethical committee for the 
present study was waived since the study does not fall within the scope of the Dutch 
Medical Research Involving Human Subjects Act (section 1.b  WMO, 26th February 1998). 
Bone scintigraphy consisted of planar images of the entire skeleton, which were 
acquired using a dual-headed camera, 2–3 hours after intravenous injection of a 
standard dosage of 550 MBq (range 515-589) of 99mTc-HDP (General Electric Millenium™ 
VG3 or General Electric Millennium™ VG5 + Hawkeye option). NaF PET/CT images were 
acquired 60 minutes after intravenous administration (90 seconds per bed position) 
of 2,5 MBq/kg body weight 18F-sodiumfluoride (Mean 189, range 146-271) on a Siemens 
Biograph-16 TruePoint PET/CT (Siemens Healthcare, Knoxville, USA). Reconstruction was 
done by means of an iterative OSEM3D algorithm using 4 iterations and 8 subsets and 
a 5 mm Gaussian filter. Reconstructed images had an image matrix size of 168 x 168, a 
pixel spacing of 4.07 x 4.07 mm and a slice thickness of 5 mm. For attenuation correction 
a low-dose CT was acquired using a tube current of 25 mAs at 110kV, collimation 16 x 1.2 
mm and a pitch of 0.95. CT images were reconstructed using a slice thickness of 5.0 mm 
and a matrix size of 512 x 512.
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All images were separately re-interpreted by two nuclear medicine physicians (M.W. 
and F.Z.) who were blinded to other imaging, biochemical, or histopathological findings 
and to the clinical follow-up. For each patient, the BS or NaF PET/CT was scored as 
no metastases, equivocal or positive for metastases. Cases demonstrating focal and 
intense tracer uptake that could not be related to benign processes were scored as 
malignant. Cases with irregular tracer uptake in the spine in the absence of other 
signs of metastases, and those with focal tracer uptake due to degenerative vertebral 
joints, were scored as no metastases. Rib lesions were categorized as malignant when 
these presented elongated uptake or when multiple randomly ordered findings of focal 
costal uptake was encountered, as benign when these vertically involved several ribs, 
and otherwise as equivocal. Low-dose CT images of the NaF PET/CT were evaluated 
for the presence of lymph node metastases, defined as lymph nodes with a short axis 
of at least 1.0 cm in the para iliac region / obturator fossa. In case of differences in 
image interpretation, decisive categorization was performed in consensus. According 
to a literature review on the role of BS in baseline staging of newly diagnosed prostate 
cancer by Abuzallouf et al. (16) patients were categorised by PSA level (<10, 10.0-19.9, 20-
49.9, 50-99.9 and >100 ng/ml) and Gleason score (≤7, ≥8 and unknown).
The used composite reference standard (RS) comprised a follow-up period of at least 18 
months for the BS cohort and at least 6 months for the NaF PET/CT cohort, and included 
staging imaging, follow-up imaging (BS, MRI, CT, X-ray, 18F-fluorocholine PET/CT, and/or 
18F-FDG PET/CT), biochemical follow-up, and clinical follow-up. 
The diagnostic performance of each modality, including sensitivity, specificity, positive 
predictive value (PPV), negative predictive value (NPV) and accuracy, were calculated 
by comparison of the BS and NaF-PET/CT results with the RS. Because both cohorts 
contained scans with equivocal results the ranges of the diagnostic performance were 
calculated both assuming that equivocal findings were positive and assuming that they 
were negative for bone metastases.
For all patients impact of BS and NaF PET/CT on clinical management was scored. For 
the retrospective BS cohort this was done by thorough survey of the electronic medical 
records. For the NaF PET/CT cohort this was scored during the urologic-oncologic 
multidisciplinary meeting. Changes in clinical management based on NaF PET/CT results 
were divided in changes based on findings of bone metastases and changes based on 
found extra-osseous metastases. 
RESULTS
The BS cohort and NaF PET/CT cohort included 136 and 107 patients, respectively. Of 
these, respectively 14 and 3 patients were excluded due to a presence of an additional 
primary malignancy. Respectively 106 and 95 patients had histopathologically proven 
prostate cancer and 16 and 9 had clinically proven prostate cancer. Histopathological 
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prove of the disease in this group was waived in case of absence of treatment options 
with curative intent or when patients refused from those potential curative options. 
Patient’s characteristics for both cohorts are presented in Table 1. 
Table 1. Patient characteristics.
BS NaF PET/CT
N 122 104
















With BS and NaF PET/CT respectively, lesions characteristic for bone metastases were 
found in 33/122 and 61/104 patients (27% and 59%), no signs of metastases were found 
in 61/122 and 40/104 (50% and 39%) patients, and for 28/122 and 3/104 (23% and 3%) 
results were equivocal. Figure 1 shows the findings for PSA categories < 10, 10-19.9, 20-
49.9, 50-99.9 and ≥ 100 ng/ml and Figure 2 displays the findings for categories Gleason 
≤7, ≥8 and unknown Gleason score. Figure 3 and 4 show examples of BS and NaF PET/CT 
with equivocal results. For all patients with signs of bone metastases curative options 
were abandoned.  
For two cases in the BS cohort no RS was available: one patient died six weeks after BS 
due to cardiovascular disease, and one patient went to another hospital for a second 
opinion. These were excluded from further analysis. For the remaining 120 BSs and the 
104 NaF PET/CTs, the imaging findings were compared with the RS and subsequently 
the diagnostic characteristics were calculated for both equivocal BSs and NaF PET/CTs 
considered positive and negative (Table 2). Found sensitivities ranged from 84.2 to 94.7% 
and from 96.8 to 100% for BS and NaF PET/CT and found specificities from 72.0 to 100% 
and 97.6 to 100%, respectively. Overall accuracy of BS ranged from 79.2 to 95.0% and for 
NaF PET/CT from 98.1 to 99.0%.
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Figure 3. Anterior and posterior 99mTc-HDP bone scan showing non-specific increased HDP uptake 
dorsally in the left 9th rib (red arrow). Subsequent X-thorax shows no signs of metastases. Patient 
received external radiation therapy with curative intent on the prostate in 2012. PSA levels decreased 
and PSA remained undetectable (<0,1 ng/ml) until the latest measurement in August 2016.
Table 2. Diagnostic characteristics of BS and NaF-PET/CT.
BS1 (%) BS2 (%) NaF PET/CT1 (%) NaF PET/CT2 (%)
Sensitivity 94.7 84.2 100 96.8
Specificity 72.0 100 97.6 100
PPV 61.0 100 98.4 100
NPV 96.7 93.2 100 95.3
Accuracy 79.2 95.0 99.0 98.1
Equivocal prevalence 23.0 23.0 2.9 2.9
Disease prevalence 31.7 31.7 60.6 60.6
1Equivocal findings considered positive, 2Equivocal findings considered negative. PPV: positive 
predictive value, NPV: negative predictive value.
According to the reference standard 5/28 (18%) equivocal findings in the BS cohort 
were due to the presence of bone metastases, the other 23/28 (82%) equivocal findings 
were due to benign causes including degenerative disease. Equivocal findings resulted 
in additional imaging procedures in 19/28 patients (16% of the patients in the entire 
cohort) which included: MRI pelvis and total vertebral column in 10 patients, CT abdomen 
and pelvis in 3 patients, MRI and CT in 1 patient, X-ray of the pelvis in 2 patients and 
chest X-ray (including detailed costal images) in 1 patient. In the NaF PET/CT cohort 2/3 
(67%) of the equivocal findings were due to bone metastases. In 2 patients (2% of the 
patients in the entire cohort) additional imaging was used, consisting of MRI of pelvis 
and vertebral column in both patients. No additional imaging was applied in the other 
patient who refused therapy with curative intent.  
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Figure 4. NaF PET, NaF PET/CT and CT images showing increased NaF uptake in the right side of 
the os frontalis without substrate on CT, unlikely for bone metastasis (red arrows). Increased 
NaF uptake in the right 8th rib, with faint sclerosis on CT, equivocal for bone metastasis (yellow 
arrows). Increased NaF uptake in degenerative changes in the lumbar spine and enthesopathy in 
the trochanteric region at both sides (green arrows). 83-years old patient abstained from therapy 
with curative intent and androgen deprivation therapy was initiated.
In the NaF PET/CT cohort low-dose CT images showed signs of lymph node metastases 
in 52/104 (50%) patients (Figure 1C and 2C). Thirteen patients had signs of lymph node 
metastases only. According to the seventh TNM-classification for prostate cancer only 
locoregional lymphadenopathy (N1) was found in 7 of those patients. In one patient a 
histopathological biopsy of a lymph node near the right external iliac artery confirmed 
the presence of a lymph node metastasis of prostate cancer. For 5 patients, including the 
patient with histopathologically proven lymph node metastasis, the multidisciplinary 
team advised radiation therapy with curative intent combined with 3 years androgen 
deprivation therapy. For 2 patients palliative hormonal treatment was advised. One of 
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those patients had a lymph node metastasis with a short axis of 7.0 cm and the other 
patient had severe co-morbidity. Locoregional as well as non-regional lymphadenopathy 
without signs of bone metastases (N1M1a) was found in 6 patients. No histopathological 
biopsies were taken from suspected lymph nodes in this group. The multidisciplinary 
team advised palliative radiation therapy for local disease control (two T4 tumours and 
one T3b) in combination with androgen deprivation therapy for 3 patients and only 
palliative androgen deprivation for the other 3 patients. 
DISCUSSION
As a consequence of the retrospective nature of this study, differences between both 
cohorts in terms of patient characteristics were observed (Table 1). The median PSA-
value in the NaF cohort is higher compared to the BS cohort, and also Gleason score 
and T-stadium of the included patients in the NaF cohort are generally higher. As a 
result the prevalence of bone metastases in the NaF cohort is markedly higher than in 
the BS cohort (61% vs 32%). To overcome this problem the cohorts were subcategorised 
by PSA-value (Figure 1) and Gleason-score (Figure 2). In most PSA categories and all 
Gleason score categories NaF PET/CT detects bone metastases in a higher percentage of 
patients. This is also reflected by the higher sensitivity of NaF PET/CT (Table 2). Thereby 
for BS a trade-off between sensitivity and specificity is found, while this trade-off is 
almost negligible for NaF PET/CT, which results in an overall high accuracy of NaF PET/CT 
compared to the moderate to high accuracy of BS. In all subcategories BS shows higher 
numbers of equivocal findings on a per patient basis compared to NaF PET/CT. 
The presence or absence of metastasised disease at the time of initial diagnosis of 
prostate cancer has large consequences on clinical management. According to most 
guidelines bone metastases preclude therapies with curative intent, however this 
perception is shifting. There is growing evidence that an intermediate oligometastatic 
state has favourable survival outcomes compared to patients with widespread metastatic 
disease. Some patients may be curable with aggressive multimodality treatments (17). For 
oligometastatic bone metastases stereotactic body radiation therapy has been shown 
to be safe and well tolerated with high local control rates (18-20). In this perspective 
imaging techniques with higher diagnostic performances, with both high sensitivity and 
high specificity become even more important for proper selection and evaluation of 
patients suited for these aggressive therapies. 
Our findings are generally in line with previous studies, which have shown a high 
sensitivity and specificity for NaF PET/CT and in comparative studies NaF PET/CT 
performed better than BS. However literature remains scarce and most studies included 
both patients for staging and restaging of prostate cancer and included a smaller 
number of patients as compared to the cohorts in present study. 
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In a prospective study from 42 patients with prostate cancer, Langsteger et al. found a 
high diagnostic performance of NaF PET/CT with a sensitivity and specificity of 91 and 
83%, respectively (14). In 24 prostate cancer patients Even-Sapir and co-workers found a 
patient based sensitivity and specificity  of 70% and 57%, respectively, for planar bone 
scintigraphy compared to 100% sensitivity and specificity for NaF PET/CT (13). In this 
study NaF PET/CT was also compared to 99mTc-MDP SPECT, which reached a sensitivity 
of 92% and a specificity of 82%. Found differences in sensitivity and specificity between 
BS or SPECT and NaF PET/CT were significant (p<0.05). In 49 prostate cancer patients 
Damle et al. found a sensitivity of 100 and 96.9% and a specificity of 70.6 and 41.2%% 
for detection of bone metastases with NaF PET/CT and BS, respectively. The overall 
accuracy was 90% for NaF PET/CT and 78% for BS (12). Poulsen et al. compared NaF 
PET/CT with BS in 50 patients for detection of spine metastases in 50 patients (15). On 
a lesions basis (526 lesions included) they found a sensitivity and specificity of 51 and 
82% for BS and 93 and 54% for NaF PET/CT, respectively. The low specificity of NaF PET/
CT was attributed to the high number of false-positive lesions due to degenerative and 
inflammatory lesions. The low specificity found by the group of Poulsen is in contrast 
to the found high specificities found in other studies. As showed by our data the 
combination of NaF PET with CT is able to accurately differentiate benign from malignant 
NaF uptake, since benign uptake is commonly found in joints, between vertebral bodies 
and at sites of tendon insertions in contrast to bone metastases, which are normally 
found inside bones, at sites in the skeleton were bone marrow is present. Also findings 
on CT contribute to differentiation. Degenerative findings such as osteophytes and joint 
narrowing and calcifications in muscle tendons relate increased NaF uptake to benign 
processes with high accuracy.
In our cohort low-dose CT showed lymphadenopathy in the pelvis in 50% of patients. In 
25% of these patients evidence of lymph node metastases was found without evidence 
of other metastases and in most cases this resulted in changes in clinical management. 
This shows that NaF PET/CT has, in addition to better detection of bone metastases, 
additional clinical value over BS in terms of detection of lymph node metastases. When 
detection of soft tissue metastases becomes more important in the primary staging of 
prostate cancer, given the options to treat oligometastatic disease, PET/CT with other 
tracers, for example 68Ga- or 18F-PSMA, would probably be more suited than NaF PET/CT. 
However, evidence is needed that PSMA PET/CT is able to diagnose bone metastases 
with at least the same accuracy as NaF PET/CT. 
In literature high specificity of a contrast enhanced CT for detection of lymph node 
metastases is reported, while the sensitivity is generally poor (21-24). For detection of 
enlarged lymph nodes the use of a low-dose CT without intravenous contrast agents is 
insufficient and pathological lymph nodes may have been missed in our cohort, which 
is a drawback of the presented data. The recently published European Guidelines on 
prostate cancer instructs to perform at least cross-sectional abdominopelvic imaging 
(MRI or CT) and BS for intermediate-risk and high-risk prostate cancer. This would support 
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the use of a diagnostic CT with an intravenous contrast agent (9). Thereby NaF PET/CT can 
be used as a modality for both bone scan and cross-sectional abdominopelvic imaging, 
except for those patients for which MRI is indicated to stage the primary tumour.
Another limitation of the presented data is the lack of a reference with the accepted gold 
standard, which is histopathologic confirmation of the included lesions. However, even 
in a prospective trial, it would be practically impossible and ethically inappropriate to 
get histopathological confirmation of all lesions included in this study. 
CONCLUSION
The present study shows a better diagnostic performance for NaF PET/CT as compared 
to BS for detection of bone metastases in primary staging of prostate cancer patients. 
Less equivocal findings are encountered with NaF PET/CT. Further diagnostic procedures 
were needed in only 2% of patients in the NaF cohort compared to 16% in the BS cohort. 
In addition NaF PET/CT detected lymph node metastases in half of the included patients, 
which resulted in alterations in clinical management in 25% of those patients. 
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